510 related articles for article (PubMed ID: 31981048)
1. The Current State of Biologic Therapies for Treatment of Refractory Asthma.
Mavissakalian M; Brady S
Clin Rev Allergy Immunol; 2020 Oct; 59(2):195-207. PubMed ID: 31981048
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
3. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
[TBL] [Abstract][Full Text] [Related]
4. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID
Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688
[TBL] [Abstract][Full Text] [Related]
5. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies for the treatment of refractory asthma.
Hambly N; Nair P
Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
[TBL] [Abstract][Full Text] [Related]
7. Choice of biologics in asthma endotypes.
Wangberg H; Woessner K
Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):79-85. PubMed ID: 33306486
[TBL] [Abstract][Full Text] [Related]
8. Molecular Targets for Biological Therapies of Severe Asthma.
Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
Front Immunol; 2020; 11():603312. PubMed ID: 33329598
[TBL] [Abstract][Full Text] [Related]
9. Asthma Phenotypes as a Guide for Current and Future Biologic Therapies.
Hamilton D; Lehman H
Clin Rev Allergy Immunol; 2020 Oct; 59(2):160-174. PubMed ID: 31359247
[TBL] [Abstract][Full Text] [Related]
10. Biological therapies for eosinophilic asthma.
Patel SS; Casale TB; Cardet JC
Expert Opin Biol Ther; 2018 Jul; 18(7):747-754. PubMed ID: 29938543
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
12. Biologics in allergic rhinitis.
Bayar Muluk N; Cingi C
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(5 Suppl):43-52. PubMed ID: 37869947
[TBL] [Abstract][Full Text] [Related]
13. Promises and challenges of biologics for severe asthma.
Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
[TBL] [Abstract][Full Text] [Related]
14. Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma.
Chan R; RuiWen Kuo C; Lipworth B
J Allergy Clin Immunol Pract; 2020; 8(10):3363-3370. PubMed ID: 32673880
[TBL] [Abstract][Full Text] [Related]
15. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
[TBL] [Abstract][Full Text] [Related]
16. IgE and eosinophils as therapeutic targets in asthma.
Patel TR; Sur S
Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):42-49. PubMed ID: 27906698
[TBL] [Abstract][Full Text] [Related]
17. Biologics in severe asthma.
Pelaia C; Pelaia G; Crimi C; Longhini F; Lombardo N; Savino R; Sciacqua A; Vatrella A
Minerva Med; 2022 Feb; 113(1):51-62. PubMed ID: 33555158
[TBL] [Abstract][Full Text] [Related]
18. Primary care of asthma: new options for severe eosinophilic asthma.
Skolnik NS; Carnahan SP
Curr Med Res Opin; 2019 Jul; 35(7):1309-1318. PubMed ID: 30880484
[No Abstract] [Full Text] [Related]
19. How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit.
Pepper AN; Hanania NA; Humbert M; Casale TB
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1081-1088. PubMed ID: 33685606
[TBL] [Abstract][Full Text] [Related]
20. New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait!
Bel EH; Ten Brinke A
Chest; 2017 Dec; 152(6):1276-1282. PubMed ID: 28583618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
